A practical solid phase synthesis of quinazoline-2, 4-diones

Tetrahedron Letters

Volumn 39, Issue 40, 1998, Pages 7235-7238

  Shao, Hui ^a,b   Colucci, Marcus ^a   Tong, Shaojing ^a   Zhang, Hesheng ^a   Castelhano, Arlindo L ^a  

^a Cadus Pharmaceutical Corporation   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

QUINAZOLINE DERIVATIVE;

ARTICLE; CHEMICAL ANALYSIS; CHEMICAL REACTION; SYNTHESIS;

EID: 0032191551     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4039(98)01595-0     Document Type: Article

References (22)

1. 1. For recent reviews on solid phase organic synthesis, see: (a) Balkenhohl, F.; von dem Bussche-Hunnefeld; Lansky, A.; Zechel, C. Angew. Chem. Int. Ed. Engl. 1996, 35, 2288.
2. (b) Thompson, L.A.; Ellman, J.A. Chem. Rev. 1996, 96, 555.
3. (c) Special issue, Acc. Chem. Res. 1996, 29.
4. 2. For recent examples, see: (a) Russo, J. Med. Chem. 1991, 34, 1850.
5. (b) Fry, D.W.; Kraker, A.J.; McMichael, A.; Ambroso, L.A.; Nelson, J.M.; Leopold, W.R.; Conners, R.W.; Bridges, A.J. Science 1994, 265, 1093.
6. (c) Zgombick, 1995, Eur. J. Pharmacol. Mol. Pharmacol. Sect. 1995, 291, 9.
7. (d) Kotani, T.; Nagaki, Y.; Ishii, A.; Konishi, Y. J. Med. Chem. 1997, 40, 684. Recently, 3,6-substituted quinazolinediones were described as fibrinogen receptor antagonists, see: Liverton, N. J.; Armstrong, D. J.; Claremon, D. A.; Remy, D. C.; Baldwin, J. J.; Lynch, R. J.; Zhang, G.; Gould, R. J. Bioorg. & Med. Chem. Lett. 1998, 8, 483.
8. (d) Kotani, T.; Nagaki, Y.; Ishii, A.; Konishi, Y. J. Med. Chem. 1997, 40, 684. Recently, 3,6-substituted quinazolinediones were described as fibrinogen receptor antagonists, see: Liverton, N. J.; Armstrong, D. J.; Claremon, D. A.; Remy, D. C.; Baldwin, J. J.; Lynch, R. J.; Zhang, G.; Gould, R. J. Bioorg. & Med. Chem. Lett. 1998, 8, 483.
9. 3. (a) Buckman, B.O.; Mohan, R. Tetrahedron Lett. 1996, 37, 4439.
10. (b) Smith, A.; Thomson, C.G.; Leeson, P.D. Bioorg. & Med. Chem. Lett. 1996, 6, 1483.
11. (c) Gouilleux, L.; Fehrentz, J.A.; Winternitz, F.; Martinez, J. Tetrahedron Lett. 1996, 37, 7031.
12. (d) Gordeev, M.F.; Hui, H.C.; Gordon, E.M.; Patel, D.V. Tetrahedron Lett. 1997, 38, 1729.
13. 4. Canone, P.; Akssira, M.; Dahdouh, A.; Kasmi, H.; Boumzebrra, M. Heterocycles 1993, 36, 1305.
14. 5. (a) Bonjouklian, R.; Ruden, R.A. J. Org. Chem. 1977, 42, 2095.
15. (b) Chantegrel, B.; Gelin, R.A. Synthesis 1981, 315. 6.
16. Bayer, E. Angew. Chem. Int. Ed. Engl. 1991, 30, 113. As far as we can ascertain, this resin has not been exploited for solid phase organic synthesis.
17. 2O, 2 X MeOH, 3 X DCM, and dried over high vacuum overnight. The substitution on the resin was over 96% determined by element analysis of chlorine composition, and the loading capacity is as high as 1.8mmol/g based on the weight increase of polymer.
18. 4
19. -1) was observed.
20. 1H-NMR (200MHz), δ 7.05 (m, 1H), 7.25 (m, 1H), 7.50 (m, 6H), 7.70 (s, 1H), 7.90 (m, 1H), 8.15 (m, 1H); LC-MS, [M+H]=322.40, purity is 94% based on LC trace.
21. 3 cyclocleavage conditions to build an hydantoin library at room temperature, see also: (a) Matthews, J.; Rivero, R. A. J. Org. Chem. 1997, 62, 6090.
22. (b) Dressman, B. A.; Spangle, L. A.; Kaldor, S. W. Tetrahedron Lett. 1996, 37, 937.